On June 16th, Bristol-Myers Squibb (BMS) announced that its new drug for preventing kidney transplant rejection, Nulojix (belatacept), has received FDA approval for marketing. Additionally, the FDA has approved the use of this product in combination with other immunosuppressants. Nulojix is available as a 250mg lyophilized powder for injection.
07-20 / 2011